Revolution Medicines Publishes Phase 1/2 Data for Daraxonrasib in NEJM
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-03. Check what remains unresolved below before relying on it.
What does this change in the investment case for Revolution Medicines?
Statistically meaningful response rates in previously treated RAS mutant NSCLC de-risk Phase 3 approval timelines, increasing the net present value of RVMD oncology pipeline assets.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factThe New England Journal of Medicine published Phase 1/2 clinical data for daraxonrasib (RASONQUE). |
| What else was confirmed? | Reported factThe trial evaluated patients with previously treated RAS mutant non-small cell lung cancer (NSCLC). |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for RVMD yet — this is the next research task. |
| What would change the assessment? | UnknownRevolution Medicines Registrational Timeline Updates — Management conference presentations clarifying Phase 3 registration pathway with the FDA. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · The New England Journal of Medicine published Phase 1/2 clinical data for daraxonrasib (RASONQUE).
- · The trial evaluated patients with previously treated RAS mutant non-small cell lung cancer (NSCLC).
- · Results showed a 42% objective response rate (ORR) and 16.0 months median overall survival.
Public research record
Research framework · page evidenceCompleted event assessment
clinical pipeline de-risking and addressable market validation
| Type | Claim | Scope |
|---|---|---|
| Assumption | The New England Journal of Medicine published Phase 1/2 clinical data for daraxonrasib (RASONQUE). | 2026-09-03 |
| Interpretation | clinical pipeline de-risking and addressable market validation | RVMD |
Countercase, invalidators, and sources
Pivotal trial designs expand to broader RAS(ON) multi-inhibitor combination therapies.
- · Revolution Medicines Registrational Timeline Updates — Management conference presentations clarifying Phase 3 registration pathway with the FDA.
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer · 2026-09-02
What remains unresolved
- Base path
- Daraxonrasib progresses into registrational Phase 3 trials with reaffirmed regulatory support.
- Adverse path
- Subsequent Phase 3 trial replication fails to sustain Phase 1/2 response rates in broader patient populations.
- Supportive path
- Pivotal trial designs expand to broader RAS(ON) multi-inhibitor combination therapies.
- · Revolution Medicines Registrational Timeline Updates — Management conference presentations clarifying Phase 3 registration pathway with the FDA.this week
Evidence
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer2026-09-02
“The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-pretreated RAS mutant NSCLC cohort”
Supports: NEJM published Phase 1/2 data for daraxonrasib showing 42% ORR and 16.0 months median OS in RAS mutant NSCLC.